CDKN2AIP抗体 新品

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P07510(CDKN2AIP Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The CDKN2AIP antibody targets the CDKN2A-interacting protein (CDKN2AIP), a nuclear protein implicated in transcriptional regulation and cellular senescence. CDKN2AIP, also known as p16INK4a-interacting protein, binds to p16INK4a—a tumor suppressor encoded by the CDKN2A gene—and modulates its activity. This interaction influences cell cycle progression by regulating the retinoblastoma (Rb) pathway, which controls G1/S phase transition. CDKN2AIP is thought to stabilize p16INK4a, enhancing its ability to inhibit cyclin-dependent kinases (CDKs) 4/6. thereby promoting cell cycle arrest and senescence. Dysregulation of CDKN2AIP has been linked to aging-related pathologies and cancer, as altered p16INK4a signaling is common in tumorigenesis and cellular aging.

Antibodies against CDKN2AIP are primarily used in research to study its expression, localization, and interaction networks. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, helping elucidate its role in senescence pathways and cancer biology. Studies using these antibodies have revealed tissue-specific expression patterns and associations with age-related diseases. However, the functional complexity of CDKN2AIP remains under investigation, particularly its dual roles in promoting senescence and potential context-dependent oncogenic activities. Reliable CDKN2AIP antibodies are critical for clarifying its mechanistic contributions to cellular homeostasis and disease.